The mechanism underlying toyocamycin-induced XBP-1 inhibition in NAFLD/NASH remains to be clarified; however, such a study may be complicated by the presence of complex metabolic interactions in the liver. Here, XBP1 is linked to metabolic dysfunction-associated steatotic liver disease.